Neumora Therapeutics (NMRA) Share-based Compensation (2022 - 2026)

Neumora Therapeutics has reported Share-based Compensation for 5 years, with the latest figure at $7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 20.58% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $28.0 million (down 33.34% YoY), and the FY2025 full-year result was $29.9 million, down 25.29% from the prior year.
• Share-based Compensation for Q1 2026 stood at $7.4 million, roughly flat from $7.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $12.8 million in Q2 2024, with the low at $2.1 million in Q3 2022.
• Average Share-based Compensation over 5 years is $6.6 million, with a median of $7.2 million recorded in 2025.
• Year-over-year, Share-based Compensation soared 402.08% in 2024 and tumbled 43.88% in 2025.
• Tracing NMRA's Share-based Compensation over 5 years: stood at $2.8 million in 2022, then jumped by 116.73% to $6.1 million in 2023, then soared by 63.66% to $9.9 million in 2024, then slipped by 25.2% to $7.4 million in 2025, then fell by 0.03% to $7.4 million in 2026.
• The last three Share-based Compensation figures came in at $7.4 million (Q1 2026), $7.4 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.

Peer Comparison